For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...
Explore Gilead Sciences' Q3 2025 earnings: strong HIV portfolio growth, Yeztugo's rapid launch, and raised guidance.
The Boston biotech founded by Harvard professor David Sinclair is testing whether cellular reprogramming can turn back the ...
Glioblastoma (GBM), the most aggressive primary brain tumor, continues to portend a poor prognosis with median survival under ...
Generic versions of biologic drugs could hit the market without human trials and allow the market forces to bring down costs, ...
Some of the most expensive drugs currently in use are gene therapies to treat specific diseases, and their high cost limits ...
Automation will help the cell therapy sector reduce production costs, resulting in lower-priced products that increase patient accessibility.
Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is a rare inherited genetic disorder affecting 1 in 31,000 people worldwide that can develop 500-1000 Basal Cell Carcinoma (BCC) le ...
These are the best products for hyperpigmentation – tested by editors, dermatologists, and experts – to help get rid of acne ...
Advances in cancer immunotherapy from immune checkpoint modulation to adoptive cell transfer of tumour-infiltrating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback